The study found that the prophylactic use of tocilizumab 1 h before CAR-T infusion in 20 patients with relapsed/refractory lymphoma who were about to receive CD19 CAR-T cell therapy was related to the low incidence rate and severity of CRS/ICANS, and there was no adverse event related to tocilizumab [111]. The gene discussed is CD19; the disease is congenital rubella syndrome.